Ibogaine Trials Will Not Run Like Standard Phase 1 Studies

FDA is describing a high-acuity research environment

The RFI addresses substantial uncertainty around ibogaine’s cardiac and neurologic safety. FDA identifies QTc prolongation and potentially life-threatening arrhythmias, neurotoxicity observed in nonclinical studies, and uncertainty about an appropriate human starting dose among the central concerns. Published human evidence also has important limitations, including inconsistent product characterization and incomplete participant-level safety and pharmacokinetic data. ([federalregister.gov](https://www.federalregister.gov/public-inspection/2026-20427/request-for-information-design-and-safety-considerations-for-clinical-trials-involving-ibogaine-drug))

FDA’s preliminary model is an open-label, sequential dose-ascending trial. The agency suggests that an initial dose should be justified by available evidence and not exceed 10 mg/kg, with participants dosed one at a time and escalation considered only after safety review. It also raises CYP2D6 genotyping, pharmacokinetic and pharmacodynamic assessments, and possible pretreatment approaches intended to reduce QTc prolongation. ([federalregister.gov](https://www.federalregister.gov/public-inspection/2026-20427/request-for-information-design-and-safety-considerations-for-clinical-trials-involving-ibogaine-drug))

That design is not simply a more closely monitored version of an outpatient Phase 1 study. It is closer to a coordinated inpatient clinical service with research layered onto it.

Facility capability must be verified, not inferred

FDA is considering an inpatient unit capable of managing a life-threatening arrhythmia. The contemplated capabilities include continuous cardiac monitoring, a physician-led team trained in advanced cardiac life support, bedside defibrillation, medications for torsades de pointes, emergency pacing, and ventilator support. Monitoring could continue until cardiac rhythm is stable and QTc has returned near baseline, potentially for 36 hours or longer. ([federalregister.gov](https://www.federalregister.gov/public-inspection/2026-20427/request-for-information-design-and-safety-considerations-for-clinical-trials-involving-ibogaine-drug))

A feasibility questionnaire asking whether a site has “emergency equipment” or “hospital access” would not establish readiness. Sponsors need to understand where dosing occurs, who controls the unit, which services are physically available, and how quickly an intervention can be performed at 2 a.m. on a weekend.

The assessment should also cover competing clinical demand. A hospital may have telemetry beds, but that does not mean beds can be reserved for research participants through baseline monitoring, dosing, observation, and a delayed discharge. Capacity that disappears when the hospital census rises is not dependable study capacity.

• Is the research team operating its own inpatient unit, or relying on space controlled by another department?
• Can telemetry data be captured, reviewed, retained, and reconciled with the study source?
• Are defibrillation, pacing, airway support, and appropriate medications immediately available in the dosing room or unit?
• Who has authority to transfer the participant to a higher level of care?
• How are research procedures maintained during an emergency transfer or prolonged hospitalization?

The staffing model has to survive the night shift

FDA’s finalized psychedelic-drug guidance recommends at least two monitors during an administration session, including a licensed healthcare provider with appropriate resuscitation training. The ibogaine RFI adds that one monitor should be a licensed mental health professional and anticipates assessment for ataxia, seizures, suicidal thoughts, psychosis, and other psychiatric symptoms. ([fda.gov](https://www.fda.gov/media/169694/download?attachment=))

A site may be able to assemble the right team for the first six hours after dosing. The harder question is whether it can maintain qualified coverage through a multi-day admission without unsafe handoffs, excessive overtime, or reliance on personnel who are unfamiliar with the protocol.

The staffing plan should identify responsibility for cardiac monitoring, psychiatric and neurologic assessments, investigational product accountability, adverse-event documentation, emergency decisions, and communication with the sponsor. It should also define how observations made by hospital personnel enter the research record.

• Build the coverage matrix by hour, not by job title.
• Test weekend, holiday, meal-break, and unexpected-extension coverage.
• Define which staff can perform protocol assessments and which can provide clinical support only.
• Rehearse emergency roles before the first participant is dosed.

Medication washout is a care pathway, not a screening criterion

FDA is considering discontinuation before dosing of medications that may prolong QTc, slow heart rate, affect CYP2D6, or increase serotonin. The examples include methadone, buprenorphine, antipsychotics, antiemetics, and selective serotonin reuptake inhibitors. ([federalregister.gov](https://www.federalregister.gov/public-inspection/2026-20427/request-for-information-design-and-safety-considerations-for-clinical-trials-involving-ibogaine-drug))

For participants with opioid use disorder, this is particularly consequential. Methadone and buprenorphine are evidence-based treatments associated with lower mortality while patients remain in treatment. Research has also identified the period after opioid agonist treatment ends as a time of increased mortality risk. FDA therefore specifically asks how discontinuation should be managed and how risks associated with loss of opioid tolerance should be mitigated. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34076676/?utm_source=openai))

Operationally, a site cannot simply instruct a potential participant to stop treatment and return for dosing. The protocol needs a defined transition process, coordination with the participant’s treating clinician, withdrawal and relapse monitoring, clear eligibility confirmation, and a plan for participants who discontinue medication but never receive study drug.

This transition may also become a major source of screen failure and withdrawal of consent. Feasibility projections should separate people who appear eligible in a database from those who can safely and voluntarily complete the required clinical pathway.

Sequential dosing changes enrollment economics

One-at-a-time dosing with review before cohort escalation may be appropriate for safety, but it creates a stop-start operating model. A single event can pause additional dosing while a safety review committee, independent data and safety monitoring board, sponsor, and possibly FDA review the data.

FDA’s contemplated stopping events include sustained ventricular arrhythmia, seizure, prolonged QTc above 500 milliseconds, new suicidality after acute effects, lasting perceptual disturbance, a possibly related serious adverse event, or multiple severe events within a cohort. The proposed oversight groups would include cardiology, neurology, psychiatry, biostatistics, and addiction medicine expertise when participants have opioid use disorder. ([federalregister.gov](https://www.federalregister.gov/public-inspection/2026-20427/request-for-information-design-and-safety-considerations-for-clinical-trials-involving-ibogaine-drug))

That cadence affects nearly every forecast. Enrollment cannot be modeled as a steady monthly rate. Bed reservations, specialist availability, pharmacy preparation, participant travel, and staff scheduling must accommodate safety-review windows and unplanned pauses. Budgets should address repeated readiness periods, unused reserved capacity, extended admissions, and rescheduling after dose-escalation decisions.

Discharge is a protocol procedure with its own failure points

FDA is considering at least 36 hours in a telemetry-monitored unit and gives a 48-hour 12-lead ECG without QTc prolongation as an example discharge criterion. It also contemplates physician approval and transportation home with a trusted adult. Cognitive testing could continue at intervals for up to 12 months. ([federalregister.gov](https://www.federalregister.gov/public-inspection/2026-20427/request-for-information-design-and-safety-considerations-for-clinical-trials-involving-ibogaine-drug))

This creates practical questions that should be answered before activation. Who pays for an extra night if discharge is delayed? What happens when an escort cancels? How far may a participant travel after discharge? Who responds if symptoms emerge after the participant leaves the unit? Can the site retain participants for long-term cognitive assessments after an intensive but brief intervention?

For studies involving substance use disorder or PTSD, follow-up cannot depend solely on automated reminders. Sites will need consented contact alternatives, structured post-discharge outreach, rapid escalation pathways, and retention plans that account for housing instability, transportation barriers, changes in treatment, and participant discomfort with returning to the dosing environment.

What meaningful feasibility should ask

The most important lesson from the RFI is not that every research site should develop inpatient psychedelic capability. Many should not. The lesson is that sponsors must select sites according to the actual risk and workflow of the protocol rather than investigator enthusiasm, therapeutic-area experience, or historical enrollment alone.

A strong feasibility process should require evidence of the complete operating system: the inpatient setting, emergency response, qualified overnight staffing, specialist coverage, controlled-substance readiness, medication-transition pathways, source-document integration, discharge logistics, and long-term follow-up capacity.

FDA is accepting comments through November 20, 2026, and its preliminary model may change. Even so, the operational questions are already useful. High-risk early-phase trials succeed when site capability, protocol design, and participant protection are evaluated together. Treating those as separate workstreams only postpones the difficult decisions until after startup. ([fda.gov](https://www.fda.gov/news-events/press-announcements/fda-seeks-public-input-support-ibogaine-research))

• Can the site demonstrate each critical capability with personnel, equipment, agreements, and written workflows?
• Which services depend on hospital partners, and are those commitments documented?
• Has the sponsor budgeted for multi-day occupancy, staffing extensions, screen failures, and dosing pauses?
• Does the medication-transition plan protect participants who do not proceed to dosing?
• Are discharge and long-term retention workflows operational before the first admission?